Just reported
Q3 2026 results
From Koru Medical Systems, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Revenue
Actual
$11.6M
+11% y/y ↑
-4.0% q/q ↓
EPS, GAAP
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $11.6M | $10.4M | +11.19% |
| Profit | $218.1K | -$778K | +128.04% |
| Profit per share | $0.00 | -$0.02 | +100.00% |
| Free Cash Flow | -$1.2M | $13K | -8,972.65% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingKoru Medical Systems, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Total Revenue of $11.6 million represents another quarter of consistent above-market growth for KORU, driven by our recurring patient base,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$3.22
Nov 9, 2026
Close after
$3.89
Nov 11, 2026
Move
+20.81%
0 shares traded, against a normal 170.59K
What Koru Medical Systems, Inc. does
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60 ® and FreedomEDGE ® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Koru Medical Systems, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
